NCT00968240 - Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions

Glioblastoma MultiformeAnaplastic Astrocytoma

Interventions

DRUG

Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB

"This phase I clinical research trial will test the hypothesis that Bevacizumab can be safely used by direct intracranial superselective intraarterial infusion up to a dose of 10mg/kg to ultimately enhance survival of patients with relapsed/refractory GBM/AA.~Day 0: Intraarterial Avastin single dose (starting at 2mg/kg and up to 10mg/kg) after Mannitol to open the blood brain barrier."

Trial Locations (1)

10075

Lenox Hill Brain Tumor Center, New York